SUBSCRIBE: Print / eNewsletter
Ahead of the ASCO Annual Meeting, we discuss the use of genomic profiling to guide treatment decisions for ER+ breast cancer patients with Harold J. Burstein, MD, PhD.
Contrary to some expectations, getting accelerated approval for neoadjuvant therapy does not look easy, and the pertuzumab story may be the exception that proves the rule.
Over the past decade, the oncology community has made significant progress in the development of highly effective treatment modalities for breast cancer. Moreover, our increasing knowledge of the molecular biology of cancer has engendered the potential to use gene expression profiling, molecular fingerprinting, and biomarkers to add increased, patient-specific value to our clinical decision making. More than ever, today’s clinician must keep up to date on the rapid scientific advances in breast cancer management.
Anthracycline- and taxane-based adjuvant chemotherapy regimens have become the most commonly used regimens in the United States for high-risk, early-stage breast cancer. Growth factor support is an essential component of therapy for several of the most commonly used adjuvant chemotherapy regimens that frequently cause substantial myelosuppression and anemia. Extensive data now exist to demonstrate the efficacy of both long- and short-acting myeloid growth factors in patients receiving dose-dense AC → paclitaxel. This article will explore prophylactic use of both filgrastim (Neupogen) and pegfilgrastim (Neulasta) in recent clinical trials.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
